Unlike previously used TKIs, such as sunitinib, pazopanib, and axitinib, cabozantinib targets MET in addition to VEGFR and may be effective as a treatment for RCC cells that are resistant to other TKIs [34]. The gene discussed is KDR; the disease is renal cell carcinoma.